Novel Device used to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment

用于优化肺动脉高压治疗气雾剂药物输送的新型装置

基本信息

批准号：
10080872
负责人：
John E Porterfield
金额：
$ 25.18万
依托单位：
BRIDGESOURCE MEDICAL CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10080872
关键词：
Aerosols Affect Air Movements Area Arteries Asthma Back Blood Circulation Breathing Bronchitis Caliber Cessation of life Chronic Obstructive Airway Disease Clinical Clinical Research Consult Deposition Device Designs Devices Diagnosis Disease Disease Management Dose Drug Delivery Systems Drug Formulations Ensure Exhalation Goals Heart Heart failure Hour Housing Iloprost Inhalation Inhalation Therapy Lead Leadership Left Life Life Expectancy Lung Lung diseases Measurement Medial Medical Nebulizer Oral Particle Size Patients Pattern Pharmaceutical Preparations Pharmacologic Substance Pharmacology Pharmacotherapy Pharmacy facility Pharyngeal structure Phase Physician Executives Population Principal Investigator Prostaglandins Pulmonary Hypertension Radial Radiolabeled Research Research Personnel Resolution Respiration Disorders Respiratory Therapy Saline Small Business Innovation Research Grant Speed Spottings System Techniques Testing Texas Time Treprostinil United States Food and Drug Administration Universities aerosolized austin base commercialization compliance behavior dosage effective therapy experience expiration hypertension treatment improved improved outcome mechanical force medication administration novel older patient outcome forecast particle pressure professor prototype pulmonary arterial hypertension respiratory sensor therapeutic target tool wasting

项目摘要

Abstract Aerosol inhalation therapy is one of the cornerstones of respiratory therapy. The size of airborne particles determines their deposition pattern within the lungs and therefore, the efficacy of inhalation therapy. In this Phase 1 SBIR project, BridgeSource Medical (BSM) proposes to develop a breath-adaptive nebulizer with variable aerosol droplet sizes and actuation times. This can be used to administer precise doses of pharmaceutical drugs to the systemic circulation with much greater efficiency than currently available aerosol delivery devices like small-volume adaptive aerosol delivery (AAD) nebulizers that require strict patient breath timing, but do not vary droplet size. The nebulizer would be particularly beneficial in the administration of medications to treat elderly patients with respiratory conditions such as pulmonary hypertension, where long treatment times and strict requirements on patient breathing lead to poor compliance. The ultimate goal will be to develop a clinical tool that would be approved by the Food and Drug Administration (FDA) as an effective system to nebulize several drug formulations targeted for patients who cannot easily comply with strict breathing maneuvers, such as the those with advanced lung disease.

抽象的气溶胶吸入疗法是呼吸疗法的基石之一。空降的大小颗粒确定其在肺部内的沉积模式，因此，吸入疗法。在此阶段1 SBIR项目中，Bridgesource Medical（BSM）提议开发具有可变气溶胶液滴尺寸和驱动时间的呼吸自适应雾化器。这可用于将精确剂量的药物用于全身性药物与当前可用的气溶胶递送设备（如诸如小体积自适应气溶胶输送（AAD）雾化器需要严格的呼吸时间，但是不要改变液滴尺寸。雾化器将在管理方面特别有益用呼吸疾病（例如肺部）治疗老年患者的药物高血压，较长的治疗时间和对患者呼吸的严格要求导致依从性差。最终目标是开发一种临床工具，该工具将由食品药品监督管理局（FDA）是一种有效的系统，用于扭转几种药物针对无法轻易遵守严格呼吸动作的患者的制剂，例如患有晚期肺部病的人。